Merck Gets Nonprescription Approval For Zocor In U.K.
This article was originally published in The Pink Sheet Daily
Executive Summary
MHRA approves Merck’s 10 mg simvastatin tablets to reduce the risk of a first major coronary event in a moderate-risk population. Marketed by McNeil Europe, Zocor Heart-Pro will be the first statin sold without a prescription in the world.
You may also be interested in...
U.K. Public "Experiment" With OTC Zocor Challenged In Lancet Editorial
An editorial in the medical journal suggests that a surveillance system be put in place to monitor use of OTC simvastatin. Zocor was approved for behind the counter sale in the U.K. May 12.
U.K. Public "Experiment" With OTC Zocor Challenged In Lancet Editorial
An editorial in the medical journal suggests that a surveillance system be put in place to monitor use of OTC simvastatin. Zocor was approved for behind the counter sale in the U.K. May 12.
Zocor Behind-The-Counter Sales Slated To Begin This Summer In U.K.
The Medicines & Healthcare products Regulatory Agency will issue an announcement May 12 on the switch application. Zocor Heart-Pro would be marketed by McNeil Europe at a price of $0.71-$1.24 per day.